FDA Warning Letters to Foreign Facilities Soar in 2017

Drug GMP Report
A A
FDA warning letters to foreign drug and API manufacturing facilities have increased more than tenfold so far this year compared to the same period in 2016.

To View This Article:

Login

Subscribe To Drug GMP Report